A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma

Cancer type: Pancreatic cancer

Phase: I/II

Principal Investigator: Guren Tormod

Country: NO

Keywords: Oleclumab, Anti-cluster of differentiation[CD]73, Norway, Pancreatic Ductal Adenocarcinoma (PDAC)

Status: Inclusion completed

Link to